Fecal microbiota transplantation dosing regimen accelerates clinical resolution in canine parvovirus infection: a novel spectrum-of-care approach.

FMT as adjunctive CPV therapy reduces hospitalization length and medication needs.

This prospective, double-blinded, placebo-controlled clinical trial evaluated fecal microbiota transplantation (FMT) as adjunctive therapy for canine parvovirus infection in 27 client-owned dogs. The FMT protocol consisted of a single enema administration followed by 14 days of oral lyophilized capsules, while controls received saline enema and placebo capsules. Both groups received conventional CPV treatment. The study was ethically discontinued after interim analysis revealed 37.5% study withdrawals in the placebo group due to clinical deterioration versus 0% in the FMT group. FMT-treated dogs demonstrated significantly shorter hospitalization duration and reduced medication requirements compared to placebo recipients. Notably, FMT did not decrease fecal viral shedding or stimulate measurable host immune responses. Both in-house and commercially available FMT products proved effective, suggesting this novel dosing regimen—designed for inpatient or outpatient feasibility—accelerates clinical recovery from CPV and expands therapeutic options for affected dogs.

This summary was distilled by AI and may occasionally misinterpret data. Confirm critical details with the primary literature before clinical application.